ATAGI update following weekly COVID-19 meeting – 1 June 2022

An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their weekly meeting on 1 June 2022.

Date published:
General public

Latest recommendation updates

ATAGI have not made any recommendations since 25 May 2022.

Recent ATAGI considerations

On Wednesday 1 June 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. As of 30 May 2022, 59 million doses of COVID-19 vaccines have been administered in Australia.

With increasing numbers of influenza infections, ATAGI recommends everyone in Australia over the age of 6 months should receive an influenza vaccination. The influenza vaccine can be given at the same time as a COVID-19 vaccine and should not be delayed.

As part of an ongoing review of existing recommendations, ATAGI continues to examine data with respect to COVID-19 booster use in people aged 12-15 years and is currently finalising advice for those in this cohort most at risk of severe disease.

ATAGI will continue to review all available and emerging evidence on the use of COVID-19 vaccines.

Ongoing review of adverse events and safety information

The TGA Weekly Report provides a detailed breakdown of adverse events following immunisation, including Australian rates of myocarditis and pericarditis.

Next meeting

The next ATAGI COVID-19 Working Group meeting will be held in late June. The Working Group will continue to progress its work out of session during this time.

Resources and recent statements

More information can be found in the following resources:

More information can be found on the Department of Health website, with resources for both providers and patients.

Help us improve

If you would like a response please use the enquiries form instead.